AUTHORS
Anthony Selwyn Stein, MD, Monzr M. M Al Malki, MD2, Dongyun Yang, PhD3, Ibrahim Aldoss, MD4, Vaibhav Agrawal, MD5, Haris Ali, MD6, Idoroenyi Amanam, MD7, Ahmed Aribi, MD8, Andrew Artz, MD,MS9, Brian John Ball, MD, MS10, Pamela S. Becker, MD, PhD11, Amanda Blackmon, DO12, Ji-lian Cai, MD13, Savita Dandapani14, Chunhui Han, PhD15, Leonardo T Farol16, Susanta Hui17, Paul Koller, MD18, An Liu19, Ryotaro Nakamura, MD20, Salman Otoukesh, MD21, Hoda Pourhassan, MD22, Vinod Pullarkat, MD23, Firoozeh Sahebi24, Amandeep Salhotra, MD25, Karamjeet Singh Sandhu, MD26, James Sanchez, PhD27, Stephanie Yoon28, Guido Marcucci, MD29, Stephen J. Forman, MD30, Joycelynne Palmer, PhD31, Jeffrey Wong, MD32
AFFILIATIONS
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 City of Hope, Duarte, California, United States, Kaiser Permanente, Los Angeles, California, United States
14 City of Hope, Duarte, California, United States
15 City of Hope, Duarte, California, United States
16 City of Hope, Duarte, California, United States, Kaiser Permanente, Los Angeles, California, United States
17 City of Hope, Duarte, California, United States
18 City of Hope, Duarte, California, United States
19 City of Hope, Duarte, California, United States
20 City of Hope, Duarte, California, United States
21 City of Hope, Duarte, California, United States
22 City of Hope, Duarte, California, United States
23 City of Hope, Duarte, California, United States
24 City of Hope, Duarte, California, United States, Kaiser Permanente, Los Angeles, California, United States
25 City of Hope, Duarte, California, United States
26 City of Hope, Duarte, California, United States
27 City of Hope, Duarte, California, United States
28 City of Hope, Duarte, California, United States
29 City of Hope, Duarte, California, United States
30 City of Hope, Duarte, California, United States
31 City of Hope, Duarte, California, United States
32 City of Hope, Duarte, California, United States
ABSTRACT
Background: In a randomized study comparing fractionated total body irradiation (fTBI) at 1200 cGy versus 1575 cGy in patients with acute myeloid leukemia (AML), the higher dose of radiation was shown to decrease relapse but not improve overall survival (OS) because of increased radiation-related toxicities (Clift et al Blood 1990). Conversely, we have found that dose escalation of organ-sparing whole-body radiation using 2000 cGy total marrow and lymphoid irradiation (TMLI) with chemotherapy results in favorable outcomes in patients with relapsed/refractory acute leukemia, with encouraging non-relapse mortality (NRM) (Stein et al Lancet Haematol 2026). In this study, for patients with AML in first or second remission, we have used TMLI 2000 cGy without chemotherapy as the pre-transplantation conditioning regimen and combined it with post-transplant cyclophosphamide (PTCy) and tacrolimus. We hypothesized that, because AML has a dose-response to radiation, TMLI may optimally complement PTCy, as the latter may be associated with increased relapse risk but might accordingly reduce the incidence of graft-versus-host disease (GVHD).
Methods: Key eligibility criteria were age 16 – 60 years, measurable residual disease–negativity by multicolor flow cytometry, and matched sibling or unrelated donor. Criteria also included adequate cardiac, liver, pulmonary, and kidney function, as well as Karnofsky performance status ≥70%. Patients were treated with TMLI 2000 cGy from day -4 to day 0, given as twice-daily 200 cGy fractions. All patients received peripheral stem cells after the last dose of radiation. GVHD prophylaxis consisted of post-transplant cyclophosphamide 50 mg/kg given on days +3 and +4, and tacrolimus given from day +5 to day +90, after which it was tapered. The primary endpoint was 1-year GVHD/relapse-free survival (GRFS). Secondary endpoints included 2-year estimation of NRM, OS, relapse-free survival (RFS), and acute and chronic GVHD.
Results: Between 03/2018 and 12/2019, we enrolled the first 18 patients of the study in a single-center pilot trial. After no unacceptable toxicities were observed (Stein et al Transplant Cell Ther 2022), we enrolled an additional 37 patients from 03/2022 to 01/2026 in an expanded phase 2 study. We report results of this study on all 55 patients (clinical trials.gov: NCT#03467386).
Patient characteristics are as follows: The median age was 43 years (range 19-60), and 32 female patients (58%) were enrolled. The races were Caucasian (n=37, 67%), Asian (n=12, 22%), Native American (n=1, 2%), and unknown (n=5, 9%). Seventeen patients (31%) were Hispanic or Latino.
A total of 46 (84%) and 9 (16%) patients were in first and second CR, respectively. European LeukemiaNet (ELN) risk distribution was 5 (9%) favorable, 31 (56%) intermediate, and 19 (35%) adverse. There were 41 (75%), 10 (18%), and 4 (7%) patients with Hematopoietic Cell Transplantation–Specific Comorbidity Index scores of 0, 1, and ≥2, respectively. A Karnofsky Performance Score of 90 or more was found in 51 (93%) patients. Twenty patients (36%) had a matched related donor, whereas 35 (64%) had a matched unrelated donor.
The median on-study follow-up was 24.1 months (range:5.3-26.2) among 51 survivors. Among all patients, the 1-year GRFS rate was 71% (95%CI: 56-81%), meeting the primary endpoint of improving 1-year GRFS from 45% to 61%. The incidence of grade II-IV acute GVHD by day 100 was 7% (95%CI: 2-16%) and grade III-IV was 2% (95%CI: 0-9%). The incidence of chronic GVHD was 20% (95%CI: 10-32%), and moderate to severe was 6% (95%CI: 2-15%).
The one-year OS, RFS, and relapse rates were 100%, 89% (95%CI: 77-95%), and 11% (95%CI: 5-21%), respectively. At 2 years, relapse was 14% (95%CI: 6-25%), and NRM remained at 0%. Additionally, the two-year OS and RFS rates were 90% (95% CI: 76-96%) and 86% (95%CI: 73-93%). The 4 deaths on study were from progressive disease.
Conclusions: The TMLI + PTCy regimen was well tolerated and led to no NRM. All patients engrafted, with a low incidence of acute and chronic GVHD, without the use of mycophenolate for GVHD prophylaxis. The use of organ-sparing TMLI + PTCy allows for safe dose escalation beyond conventional TBI with encouraging RFS and without increased toxicities. This regimen warrants further evaluation as a potential replacement to current myeloablative TBI regimens.
DISCLOSURES
Anthony Selwyn Stein, MD: Syndex Bio - Honoraria; Amgen - Honoraria; Debio - Honoraria; Debio - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Syndex Bio - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)